Months after cancer drug trial, Merus agrees to be bought at 41% premium
Short excerpt below. Click through to read at the original source.
Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.
Short excerpt below. Click through to read at the original source.
Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.